Initial Findings Show Promise in Treating Skin Conditions
SYDNEY — Rubedo Life Sciences has announced positive preliminary results from its Phase 1 clinical trial of RLS-1496, targeting plaque psoriasis, atopic dermatitis, and skin aging. Conducted in the European Union, the trial met its primary endpoint, according to a company statement released this week.
The trial evaluated the safety and efficacy of RLS-1496, a GPX4 modulator, showing significant clinical improvement in psoriasis and atopic dermatitis patients. “We observed very promising results across multiple measures,” said Rubedo CEO Frederick Beddingfield, III, MD, PhD.
Rubedo has commenced a Phase 1b/2a study in actinic keratosis in the United States, expected later this year. The company plans to present further findings at upcoming dermatology conferences.
Clinical Trial Insights
During the European trial, RLS-1496 demonstrated a clear dose-response and was well-tolerated, with no serious adverse events reported. In psoriasis patients, significant target engagement and reduction in senescent cells were observed. Atopic dermatitis subjects showed even higher levels of target engagement, with substantial clinical improvement.
According to Marco Quarta, PhD, Chief Scientific Officer at Rubedo, these results offer insight into the drug’s potential as a novel therapeutic option targeting aging cells in dermatological conditions.
This announcement aligns with growing interest in cellular rejuvenation therapies, as the biotechnology sector increasingly focuses on age-related diseases. The success of RLS-1496 in preliminary trials paves the way for Rubedo Life Sciences to explore further development opportunities, potentially collaborating with other pharmaceutical companies. The ongoing research and upcoming trials will be closely monitored by stakeholders and investors looking to advance the field of dermatological therapeutics.
As the biotechnology industry continues to innovate, the potential for breakthroughs in treatments for skin conditions grows. The promising results from the RLS-1496 trial underscore the importance of continued investment in research and development to address unmet medical needs and improve patient outcomes worldwide.
Source: newshub.medianet.com.au
Last updated: 1 April 2026, 10:26 am
